Tongjitang Pins Loss On Delayed Implementation Of China's Essential Drug List; Proposed Buyout Still Under Review
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Tongjitang, the first traditional Chinese medicine company listed on the New York Stock Exchange, reported a $694,000 net loss during the second quarter for the year, attributing it to increased sales and marketing expenses for sales infrastructure and its essential drug sales network
You may also be interested in...
Local Chinese Companies With Mix Of TCM And Western Medicines Poised For Strong Growth
HONG KONG - Tongitang Chinese Medicines Company, a developer and manufacturer of modernized traditional Chinese medicines is streamlining its operations by getting rid of less profitable segments and expanding its pipeline
Local Chinese Companies With Mix Of TCM And Western Medicines Poised For Strong Growth
HONG KONG - Tongitang Chinese Medicines Company, a developer and manufacturer of modernized traditional Chinese medicines is streamlining its operations by getting rid of less profitable segments and expanding its pipeline
3SBIO Sees Slowdown In China Regulatory Approvals Following SFDA Restructure; Concerns Linger On Drug Pricing Examination
SHANGHAI - Chinese biotech outfit 3SBio reported strong sales growth of its key products, recombinant human erythropoietin injection EPIAO and recombinant human thrombopoietin injection TPIAO, but like many companies in China, 3SBio's development plans are impacted by a regulatory slowdown caused by restructuring at China's State FDA